Biomedicine and Pharmacotherapy Submission Guide

Source: Clarivate JCR 2024, Elsevier editorial disclosures (accessed April 2026).

Source: Biomedicine and Pharmacotherapy author guidelines.

Use this page when deciding:

• whether the pharmacotherapy contribution is substantive

• whether mechanism of action is articulated

• whether in-vivo validation is rigorous

• a clear pharmacotherapy contribution

• mechanism of action evidence

• in-vivo validation

• translational relevance

• a cover letter establishing the contribution

• Descriptive activity reports without mechanism.

• Weak in-vivo validation.

• Missing clinical relevance.

• Pure chemistry without pharmacotherapy focus.

Biomedicine and Pharmacotherapy is a flagship pharmacotherapy research journal.

Mechanism + translational standard: the journal differentiates from Pharmacological Research (broader) and Phytomedicine (natural-product focused) by demanding pharmacotherapy with mechanism and translational support.

In-vivo expectation: editors expect animal models or comparable validation.

The 30-40% desk rejection rate: decisive editorial screen.

The strongest Biomedicine and Pharmacotherapy editor-facing notes establish:

• the pharmacotherapy contribution

• the mechanism of action

• the in-vivo validation

• the translational relevance

Biomedicine and Pharmacotherapy submissions go through Elsevier Editorial Manager at Editorial Manager submission portal. Initial setup requires an Elsevier account; ORCID is recommended for the corresponding author. The platform accepts manuscript file (.docx, .pdf, or .tex), figure files (separate uploads), supplementary information, and a cover letter as a separate document.

Biomedicine and Pharmacotherapy requires these at first submission:

• Cover letter explicitly justifying clinical or translational relevance (the journal filters heavily on translational potential)

• Declaration of competing interests for all authors

• Ethics approval statement for any animal or human work (IACUC or IRB number required)

• Informed consent statement for human-subject research

• Data availability statement with repository links where applicable

• CRediT author contributions statement

• 4+ suggested reviewers with no recent collaboration history

• Reporting checklist for the relevant study type (ARRIVE for animal work, CONSORT for trials, STROBE for observational)

For Biomedicine and Pharmacotherapy submissions, the most common artifact-related desk-reject is missing or generic ethics statements. Elsevier intake reviewers flag IACUC numbers and IRB approval codes specifically; vague "appropriate ethics approval was obtained" language commonly triggers a return for revision.

For Biomedicine and Pharmacotherapy submissions, the editorial timeline runs through four phases. The journal moves faster than most Elsevier biomedical titles, but the editorial filter on translational relevance is strict.

Day 0 to 3: Editorial Manager intake and editor assignment

Elsevier intake handles format compliance plus the ethics-statement check. The handling Editor assignment lands within 3 days; biomedicine papers route to subject editors with matching pharmacology or therapeutics expertise. The most common Day 0-3 hold-up: incomplete ethics statements or missing reporting-checklist completion.

Day 3 to 14: Editor scope screen

B&P editors apply a translational-relevance filter: does the work connect to a clinical or pre-clinical application context? The most common Day 3-14 desk reject in our review work: pure mechanism-of-action papers without explicit therapeutic-application framing. The journal accepts mechanistic work, but the cover letter must connect it to a named clinical or pharmacological problem.

Week 2 to 5: Peer review

Standard 2-3 reviewers, 3-5 week first decision target (fast for Elsevier biomedical). Reviewer mix typically includes one pharmacology expert plus one application-domain specialist. Submissions missing dose-response data, pharmacokinetic context, or comparator-drug benchmarks extend reviewer dialogue by 2-3 weeks.

Week 5 to 14: Decision, revision, and production

Minor or major revision is the standard first decision at B&P. Revision rounds typically settle at 1-2. Total submission-to-acceptance: 3-5 months for accepted papers. Open-access option available with APC at acceptance.

• Biomedicine and Pharmacotherapy journal overview

• Phytomedicine submission guide for natural-product pharmacology papers where Phytomedicine may be the cleaner journal owner.

Before upload, run your manuscript through a Biomedicine and Pharmacotherapy mechanism check.

The sources above define the mechanics; the harder question is whether this draft earns review. The review tells you whether your paper clears the Biomedicine and Pharmacotherapy fit check before upload, especially around descriptive activity reports where the mechanism is not visible in the abstract or figures, in-vivo or translational evidence too thin for the therapeutic claim, and cover letter and scope framing that sound like pure biology rather than pharmacotherapy.

Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Across biomedical manuscripts targeting Biomedicine and Pharmacotherapy, the strongest submissions do not merely report activity. They make a pharmacotherapy argument across the abstract, figures, methods, ethics statements, cover letter, and supplementary package. Official Elsevier instructions describe the Editorial Manager route, article preparation policies, competing-interest declaration, funding disclosure, generative-AI declaration, research-data statement, and submission checklist.

The manuscript-specific question is whether the paper proves a therapy-relevant mechanism with enough in-vivo, translational, or disease-context evidence for this journal rather than a broader pharmacology, natural-products, molecular-biology, or disease-specialty venue.

Descriptive activity reports where the mechanism is not visible in the abstract or figures

In our review work with Biomedicine and Pharmacotherapy-targeted manuscripts, we often see abstracts built around "compound X inhibited pathway Y" or "extract Z reduced disease marker W" while the mechanism remains inferential. The figure package may show viability, apoptosis, inflammatory markers, enzyme inhibition, oxidative stress, or pathway-protein changes, but it does not prove how the intervention creates a pharmacotherapy-relevant effect. Editors can read that as a screening report rather than a Biomedicine and Pharmacotherapy contribution.

A stronger submission names the mechanism in the abstract, shows the key mechanistic figure in the main text, links the methods to a disease or therapeutic context, and uses the cover letter to state why the mechanism matters for pharmacotherapy. Redirect targets include Pharmacological Research, European Journal of Pharmacology, Phytomedicine, International Immunopharmacology, Molecular and Cellular Biochemistry, and disease-specialty venues. The manuscript should make clear why Biomedicine and Pharmacotherapy is the correct target, not just why the result is biologically interesting.

Check whether your Biomedicine and Pharmacotherapy mechanism claim is visible enough →

In-vivo or translational evidence too thin for the therapeutic claim

For Biomedicine and Pharmacotherapy submissions, a second recurring pattern is a mismatch between therapeutic language and evidence depth. The title, conclusion, graphical abstract, or cover letter may imply treatment relevance, but the methods rely mainly on cell lines, isolated enzymes, computational docking, network pharmacology, or descriptive omics. That can be acceptable for some discovery venues, but Biomedicine and Pharmacotherapy readers expect a clearer bridge to therapeutic use.

Stronger manuscripts include animal-model evidence, patient-derived samples, organoids, pharmacokinetic or toxicity context, dose-response logic, comparator-drug benchmarks, or a carefully constrained claim that explains what remains preclinical. The abstract should not overstate readiness, and the limitations should separate mechanistic promise from draft readiness. Required artifacts matter here: ethics approval, informed consent where applicable, ARRIVE or other reporting checklist where relevant, data availability, CRediT roles, competing-interest declarations, and supplementary methods need to support the therapeutic frame.

If those pieces are thin, the manuscript may be better routed to Phytomedicine, a pharmacology specialty journal, or a disease-field journal before Biomedicine and Pharmacotherapy.

Check whether your Biomedicine and Pharmacotherapy evidence package supports the therapeutic claim →

Cover letter and scope framing that sound like pure biology rather than pharmacotherapy

Across Biomedicine and Pharmacotherapy-targeted manuscripts, the third common problem is cover-letter and introduction framing that reads like pure molecular biology, pure chemistry, or general disease biology. The paper may be promising, but the editorial conversation is wrong. A Biomedicine and Pharmacotherapy package should state the pharmacotherapy problem, the disease context, the intervention or mechanism, the main evidence component, and the translational implication.

The manuscript components should reinforce that story: abstract, graphical abstract, figure legends, methods, references, data statement, ethics statement, and supplementary material. If the cover letter could be sent unchanged to Phytomedicine, Pharmacological Research, European Journal of Pharmacology, International Immunopharmacology, Molecular Therapy, or a disease-specialty journal, it is not specific enough.

The practical fix is to rewrite the first paragraph around the therapy-relevant mechanism, name the comparator or standard-of-care context when appropriate, and make the limitations honest about what the current draft does and does not prove.

Check whether your Biomedicine and Pharmacotherapy editor note frames pharmacotherapy fit →

A Manusights review checks whether your paper clears the Biomedicine and Pharmacotherapy-specific readiness checks that official Elsevier instructions cannot evaluate from a generic Editorial Manager checklist. Paid Manusights reviews include a 60-day money-back guarantee; submitted manuscripts are not used for model training.

Clarivate JCR 2024 bibliometric data places Biomedicine and Pharmacotherapy among top pharmacotherapy journals.

Use these nearby guides when the target journal is still uncertain:

• Chemosphere Submission Guide

• Energy Conversion and Management Submission Guide

• New Phytologist Submission Guide

• Ceramics International Submission Guide

• Journal of Alloys and Compounds Submission Guide

• Chemical Engineering Journal Cover Letter

• Engineering Structures Submission Guide

• Advanced Materials Submission Guide

• Advanced Science Submission Guide

• Advanced Functional Materials Submission Guide

Use official guidance for live requirements. For Biomedicine and Pharmacotherapy Submission Guide, the Manusights decision layer focuses on the manuscript-level fit, evidence, routing, and first-screen questions that public author instructions usually cannot answer for an individual draft.

The Manusights editorial review for Biomedicine and Pharmacotherapy Submission Guide combines official guidance, adjacent Manusights cluster pages, and first-party pre-submission review patterns. They are used here to clarify manuscript-readiness decisions, not to replace publisher instructions.

For the related journal overview, see Biomedicine And Pharmacotherapy journal guide. In our work on Biomedicine And Pharmacotherapy submissions, we observe that editors specifically screen the abstract, first figures, cover letter, and evidence package for whether the manuscript answers the journal's stated fit test; our analysis of Biomedicine And Pharmacotherapy pages treats those checks as submission-risk signals, not as official guidance.